Diabetes mellitus is one of the most prevalent conditions affecting human health including veterans in the 21st century. Most of the focus of our efforts to understand the pathogenesis and therapy of the disease has focused on two major components: insulin sensitivity and insulin secretion. However, dysregulation in glucagon secretion is a major component in diabetes. Hyperglucagonemia plays key roles in the pathogenesis of hyperglycemia in type 2 diabetes and has a major impact in the glycemic volatility and susceptibility to hypoglycemia in type 1 diabetes. Our observations published during the current funding period suggest that downstream of insulin/Akt, the nutrient sensitive pathway (mTOR/Raptor or mTORC1) plays a major role in regulation of alpha cell mass and glucagon secretion. However, how mTORC1 acting on key downstream targets (4E-BPs and S6K) regulates the function and mass of alpha-cells in vivo and the potential contribution of these targets to the regulation of glucose metabolism remain unclear. The long-term goal of these studies is to uncover how the nutrient sensitive insulin/Akt/mTORC1 axis regulates ?-cell mass and glucagon secretion in rodent models and humans. Our studies showed that loss of mTORC1 function in alpha-cells results in major abnormalities in alpha-cell mass and glucagon secretion. We also demonstrate that gain of mTORC1 results in chronic hyperglucagonemia and alpha cell mass expansion suggesting that this signaling pathway is critical for alpha cell mass and glucagon secretion. Based on these observations, we hypothesize that mTORC1 regulates alpha-cell mass mainly by a balance between S6K and 4E-BP signaling.
The specific aims will assess the individual contribution of downstream targets of mTORC1 by establishing the role of mTORC1/4E-BP/eIF4E axis in regulation of alpha-cell mass, glucagon secretion and adaptation to diabetogenic conditions using novel alpha cell specific models. In addition, we will also identify the importance of mTORC1/S6K on the control of alpha-cell mass and glucagon secretion by generation of novel models with inducible gain of S6K function in alpha cells. Finally, how mTORC1 activation alters human alpha-cell responses will be determined using a model of human islet transplantation in the anterior chamber of the mouse eye. This proposal will provide important insights into the molecular mechanisms that govern alpha-cell mass expansion by mTORC1. This information can be used to uncover novel targets that can be used for treatment of diabetes and design interventions to rescue the defects in glucagon secretion in response to hypoglycemia in patients with diabetes.

Public Health Relevance

Type 2 Diabetes (T2D) is characterized by defective adaptation of ?-cells to insulin resistance. Most of the research effort has focused on elucidating the physiological, molecular, and genetic components that regulate ?-cell mass and insulin secretion, presenting diabetes as a unihormonal disorder. Contrary to this approach, clinical data and animal experiments have shown that alterations in glucagon secretion and ?-cell mass play a role in the pathogenesis of hyperglycemia in diabetes and responses to hypoglycemia in patients with diabetes. The goal of this application is to understand how nutrient signaling regulates glucagon secretion and ?-cell mass in an effort to develop novel therapies for diabetes and control the incident of hypoglycemia, a limitans factor for optimal diabetes control. These agents could be used in translational experiments to treat diabetes and hypoglycemia by controlling glucagon secretion.

Agency
National Institute of Health (NIH)
Institute
Veterans Affairs (VA)
Type
Non-HHS Research Projects (I01)
Project #
2I01BX002728-05
Application #
9884855
Study Section
Special Emphasis Panel (ZRD1)
Project Start
2016-01-01
Project End
2024-03-31
Budget Start
2020-04-01
Budget End
2021-03-31
Support Year
5
Fiscal Year
2020
Total Cost
Indirect Cost
Name
Miami VA Health Care System
Department
Type
DUNS #
079275714
City
Miami
State
FL
Country
United States
Zip Code
33125
Navarro, Guadalupe; Allard, Camille; Morford, Jamie J et al. (2018) Androgen excess in pancreatic ? cells and neurons predisposes female mice to type 2 diabetes. JCI Insight 3:
Gregg, Brigid E; Botezatu, Nathalie; Brill, Joshua D et al. (2018) Gestational exposure to metformin programs improved glucose tolerance and insulin secretion in adult male mouse offspring. Sci Rep 8:5745
Dean, E Danielle; Li, Mingyu; Prasad, Nripesh et al. (2017) Interrupted Glucagon Signaling Reveals Hepatic ? Cell Axis and Role for L-Glutamine in ? Cell Proliferation. Cell Metab 25:1362-1373.e5
Blandino-Rosano, Manuel; Barbaresso, Rebecca; Jimenez-Palomares, Margarita et al. (2017) Loss of mTORC1 signalling impairs ?-cell homeostasis and insulin processing. Nat Commun 8:16014
Bozadjieva, Nadejda; Blandino-Rosano, Manuel; Chase, Jennifer et al. (2017) Loss of mTORC1 signaling alters pancreatic ? cell mass and impairs glucagon secretion. J Clin Invest 127:4379-4393
Alejandro, Emilyn U; Gregg, Brigid; Blandino-Rosano, Manuel et al. (2015) Natural history of ?-cell adaptation and failure in type 2 diabetes. Mol Aspects Med 42:19-41